Ignite Creation Date:
2024-05-06 @ 3:59 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04834206
Status:
COMPLETED
Last Update Posted:
2022-05-10
First Post:
2021-04-01
Brief Title:
Nedaplatin in Treatment for Nasopharyngeal Carcinoma
Sponsor:
Affiliated Cancer Hospital Institute of Guangzhou Medical University
Organization:
Affiliated Cancer Hospital Institute of Guangzhou Medical University
Study Overview
Official Title:
Induction Chemotherapy With Nedaplatin Docetaxel and 5-Fluorouracil Followed by Concurrent Nedaplatin and Radiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma a Single Arm Open Label Multicenter Phase II Clinical Study
Status:
COMPLETED
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy of induction chemotherapy with nedaplatin docetaxel and 5-Fluorouracil followed by concurrent nedaplatin combined with radical radiotherapy in locally advanced nasopharyngeal carcinoma
Detailed Description:
This is a prospective phase II clinical trial to evaluate the efficacy and safety of induction chemotherapy with nedaplatin docetaxel and 5-Fluorouracil followed by concurrent nedaplatin combined with radical radiotherapy in locally advanced nasopharyngeal carcinoma patients This is a multicenter study All patients will be enrolled in endemic area All patients will receive radical intense modulate radiation therapy IMRT The primary endpoint is objective response rate ORR
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None